SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
AZN Analysis & Videos »
AZN: Bull or Bear?
AstraZeneca & General Dynamics: Financial strength
AZN
-7.98%
in
999 days
Filed under: International markets, Newsletters, Stocks to Buy, General Dynamics Corp (GD), Financial Crisis "Investors considering high-yield stocks should consider financial strength; in our quantitative model, Quadrix, we assess profit margins, interest coverage, and debt levels," says Richard Moroney. In Dow Theory Forecasts, a newsletter that has been published for over 5 decades -- he looks at two stocks that score high in this area: drug manufacturer, AstraZeneca (NYSE: AZN) and defense industry player, General Dynamics (NYSE: GD). Here, the advisor reviews the two companies. <>"AstraZene...
|
Analyst Recommendation
AZN
|
|
|
-10.11%
in
1009 days
New AstraZeneca drug reduces heart patients' risks AstraZeneca says Brilinta anti-clotting drug reduces chance of dying better than Plavix By Maria Cheng, AP Medical Writer On Sunday August 30, 2009, 1:45 pm EDT BARCELONA, Spain (AP) -- A new drug to prevent blood clots in heart patients reduced their chances of dying by more than 20 percent compared with the standard treatment, new research says. Researchers followed 18,624 patients worldwide from 2006 to 2008. About half the patients were taking clopidogrel, also known as Plavix, while the other half were taking an experimental...
|
FDA Calendar Updates: POZN, AZN, SNY, CEPH, APPY, CYTR
AZN
|
|
|
-5.41%
in
1070 days
<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of over 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-st...
|
FDA Calendar Updates at BioMedReports.com
AZN
|
|
|
-2.24%
in
5 days
(closed on 06/30/09)
<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of over 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-st...
|
FDA, Clinical Trial Calendars: Cancer Drug Updates from ASCO
AZN
|
|
|
+7.89%
in
25 days
(closed on 06/25/09)
<> Below is a summary of updates to the BioMedReports.com database of over 200 entries included in the <font> FDA and Clinical Trial Calendars </font> . The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions to the FDA for complete respon...
|
FDA, Clinical Trial Calendar Updates: AZN, IMGN, MIPI, MELA
AZN
|
|
|
+9.36%
in
20 days
(closed on 05/31/09)
<> Below is a summary of updates to the <font> BioMedReports.com </font> database of over 200 entries included in the <font> FDA and Clinical Trial Calendars </font> . The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions to the FDA fo...
|
Updated FDA, Clinical Trial Calendars: AZN, MYGN, NVS, PSDV
AZN
|
|
|
+10.58%
in
33 days
(closed on 05/11/09)
<> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. The entries are updated on a daily basis as new information becomes available with a total of 113 entries through 4/8/09. The FDA Calendar includes the following information: company name, ticker, decision ...
|
FDA, Clinical Trial Calendar Updates: Weight Loss, Diabetes, and More
AZN
|
|
|
-3.60%
in
7 days
(closed on 04/08/09)
<> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. The entries are updated on a daily basis as new information becomes available with a total of 110 entries through 4/1/09. The FDA Calendar includes the following information: company name, ticker, decision d...
|
Upcoming FDA Advisory Panel Meetings
AZN
|
|
|
-18.57%
in
23 days
(closed on 04/01/09)
A trio of diabetes drug candidates are affected by a tougher stance at the FDA for this class of drugs, which is focused on cardiovascular risks such as heart attack and stroke. Two of the drugs will be reviewed at early April FDA advisory panel meeting while a third will likely require additional clinical trials. http://www.biomedreports.com/fda-calendar.html <> In December the FDA issued a new guidance document that recommended more stringent clinical trials for diabetes drugs to better assess heart attack and stroke risks. In a change that was effective immediately,...
|
Updated Clinical Trial and FDA Decision Calendars
AZN
|
|
|
+3.16%
in
5 days
(closed on 03/09/09)
Posted by: Mike Havrilla in Untagged on Mar 04, 2009 <!-- Post Teaser Text --> <> Below are some recent updates to the BioMedReports.com -- FDA and Clinical Trial Calendars : <> 1.) Auxilium Pharma (AUXL): 3/2/09 BLA submission with priority review request for XIAFLEX (clostridial collagenase for injection), a novel, first-in-class, orphan-designated biologic for the treatment of Dupuytren's contracture. 5/2/09 is the date for FDA to accept the filing for review and decide on prior...
|
Bullish on AZN ...
AZN
|
|
|
-10.13%
in
1427 days
Deutsche bank rating: from BUY to HOLD. Broker is waiting price in line with the sector.
|
AstraZeneca Should Clear Hurdles
AZN
-1.79%
in
1441 days
Management is determined to grow earnings largely through expanding its top-line and only secondarily through cost-cutting, share buybacks and productivity initiatives.
|
People Bullish on AZN
People Bearish on AZN
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
Be the first to start a discussion and earn 2 points.
More Resources
|
About AstraZeneca PLC
- Answers.com
